Developing A Baseline Metabolomic Signature Associated with COVID-19 Severity: Insights from Prospective Trials Encompassing 13 U.S. Centers
Authors:
- Kaifeng YangKYKaifeng Yang
- Zhiyu KangZKZhiyu Kang
- Weihua GuanWGWeihua Guan
- Sahar Lotfi-EmranSLSahar Lotfi-Emran
- Zachary J. MayerZMZachary J. Mayer
- Candace R. GuerreroCGCandace R. Guerrero
- Brian T. SteffenBSBrian T. Steffen
- Michael A. PuskarichMPMichael A. Puskarich
- Christopher J. TignanelliCTChristopher J. Tignanelli
- Elizabeth LusczekElizabeth Lusczek
- Sandra E. SafoSSSandra E. Safo
Open Access
- 24 October 2023
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 13 (11) , 1107
Abstract
Metabolic disease is a significant risk factor for severe COVID-19 infection, but the contributing pathways are not yet fully elucidated. Using data from two randomized controlled trials across 13 U.S. academic centers, our goal was to characterize metabolic features that predict severe COVID-19 and define a novel baseline metabolomic signature. Individuals (n = 133) were dichotomized as having mild or moderate/severe COVID-19 disease based on the WHO ordinal scale. Blood samples were analyzed using the Biocrates platform, providing 630 targeted metabolites for analysis. Resampling techniques and machine learning models were used to determine metabolomic features associated with severe disease. Ingenuity Pathway Analysis (IPA) was used for functional enrichment analysis. To aid in clinical decision making, we created baseline metabolomics signatures of low-correlated molecules. Multivariable logistic regression models were fit to associate these signatures with severe disease on training data. A three-metabolite signature, lysophosphatidylcholine a C17:0, dihydroceramide (d18:0/24:1), and triacylglyceride (20:4_36:4), resulted in the best discrimination performance with an average test AUROC of 0.978 and F1 score of 0.942. Pathways related to amino acids were significantly enriched from the IPA analyses, and the mitogen-activated protein kinase kinase 5 (MAP2K5) was differentially activated between groups. In conclusion, metabolites related to lipid metabolism efficiently discriminated between mild vs. moderate/severe disease. SDMA and GABA demonstrated the potential to discriminate between these two groups as well. The mitogen-activated protein kinase kinase 5 (MAP2K5) regulator is differentially activated between groups, suggesting further investigation as a potential therapeutic pathway.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-017069, 1R35GM142695)
- National Institute of General Medical Sciences (INV-017069, 1R35GM142695)
This publication has 44 references indexed in Scilit:
- Controlling the Rate of GWAS False DiscoveriesGenetics, 2017
- Extracellular signal–regulated kinase 5 promotes acute cellular and systemic inflammationScience Signaling, 2015
- Impact of serial measurements of lysophosphatidylcholine on 28-day mortality prediction in patients admitted to the intensive care unit with severe sepsis or septic shockJournal of Critical Care, 2014
- Lysophosphatidylcholine as a prognostic marker in community-acquired pneumonia requiring hospitalization: a pilot studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2014
- Causal analysis approaches in Ingenuity Pathway AnalysisBioinformatics, 2013
- The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in InflammationGenes, 2013
- Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patientsJournal of Lipid Research, 2003
- Partial least squares for discriminationJournal of Chemometrics, 2003
- On a Test of Whether one of Two Random Variables is Stochastically Larger than the OtherThe Annals of Mathematical Statistics, 1947
- X. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random samplingJournal of Computers in Education, 1900